Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

ption, then patients were placed in one of two parallel registries for PCI or CABG.

SYNTAX is breaking new ground by scientifically defining a new measure for anatomical complexity - the SYNTAX Score - which seeks to provide guidance to physicians on optimal treatment options for this high-risk group of patients. The SYNTAX Score characterizes vasculature based on lesion frequency, complexity and location, relying on data from the SYNTAX trial as well as information collected through other sources.

The safety and effectiveness of the TAXUS Express2 Stent System has not been established in patients with left main or three-vessel disease.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together w
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... , June 1, 2015 /CNW/ - Resverlogix Corp. (TSX: ... RVX-208 was presented at the ERA-EDTA Congress in ... "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key ... and Chronic Kidney Disease (CKD); a Post-hoc Analysis of ... Dr. Kam Kalantar-Zadeh , Professor ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Researchers have completed the first thorough, system-level assessment ... of microbes known as Shewanella. Microbes belonging to ... and cleaning up contaminated areas in the environment. ... Institute of Technology, Michigan State University and the ...
... ... , ... The Honolulu-based Pacific Health Research Institute (PHRI) has received $2.8 million in research funding ... a major lung cancer screening study in Hawaii, for two more years. , , , ...
... , , BOTHELL, Wash., ... a leading developer, manufacturer, and marketer of biopreservation tools for ... BloodStor biopreservation media product platform. The product family includes ... as well as other variants for peripheral blood derived stem ...
Cached Biology Technology:Hidden diversity in key environmental cleanup microbes found by systems biology assessment 2Hidden diversity in key environmental cleanup microbes found by systems biology assessment 3Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 2BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 3
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... discovered that iron-containing nanoparticles being tested for use in ... and interfere with the formation of their signal-transmitting extensions. ... and most life forms and iron oxide nanoparticles were ... professor of materials science at UCSD and senior author ...
... box glowing with fluorescent light, Stacie Grassano pulls out a tube. ... up to her face. Inside, a tree branch is speckled with ... Scott Costa. , Costa brings the branch close to his eye. ... success story." , For some, a fungus success story means ...
... announced that it has added high-density genotyping on ... list of services. Stan Nelson, the principal investigator ... for its user-base of ~10,000 investigators across the ... of the scientific community." , The Consortium ...
Cached Biology News:Widely used iron nanoparticles exhibit toxic effects on neuronal cells 2Widely used iron nanoparticles exhibit toxic effects on neuronal cells 3Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3NIH neuroscience microarray consortium launches high-throughput genotyping services 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: